☰

Randy S. Schrecengost, Ph.D. - Publications

Affiliations: 
2009 University of Virginia, Charlottesville, VA 
Area:
Cell Biology, Microbiology Biology, Oncology
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 McCann JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, McNair C, Dylgjeri E, Mandigo AC, Schiewer MJ, Schrecengost RS, Gallagher P, Stanek TJ, McMahon SB, Berman-Booty LD, Ostrander WF, Knudsen KE. USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair. Cancer Research. PMID 31740444 DOI: 10.1158/0008-5472.Can-19-1033  0.385
2018 Schrecengost RS, Green CL, Zhuang Y, Keller SN, Smith RA, Maines LW, Smith CD. In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183. The Journal of Pharmacology and Experimental Therapeutics. PMID 29434052 DOI: 10.1124/Jpet.117.245738  0.378
2018 Smith CD, Schrecengost RS, Zhuang Y, Maines LW, Keller SN, Smith RA, Green CL. Abstract B190: Antitumor effects of ABC131, a novel diaminothiazole inhibitor of tubulin Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B190  0.376
2015 Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research : McR. PMID 26271487 DOI: 10.1158/1541-7786.Mcr-14-0626  0.44
2015 Jones J, Dean JL, Schrecengost RS, Knudsen K. Abstract 1862: Discerning the role of USP22 in prostate cancer development and progression Cancer Research. 75: 1862-1862. DOI: 10.1158/1538-7445.Am2015-1862  0.426
2015 Schrecengost RS, Keller S, Schiewer M, Knudsen K, Smith C. Abstract C94: Dual downregulation of Myc and AR with a sphingosine kinase-2 inhibitor prevents prostate cancer progression Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C94  0.48
2014 Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research. 74: 272-86. PMID 24197134 DOI: 10.1158/0008-5472.Can-13-1954  0.438
2014 Schrecengost RS, Augello MA, Knudsen KE. Androgen receptor regulation of prostate cancer progression and metastasis Signaling Pathways and Molecular Mediators in Metastasis. 277-309. DOI: 10.1007/978-94-007-2558-4_12  0.328
2013 Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Seminars in Oncology. 40: 244-58. PMID 23806491 DOI: 10.1053/J.Seminoncol.2013.04.001  0.406
2013 Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. Plos One. 8: e65678. PMID 23762409 DOI: 10.1371/Journal.Pone.0065678  0.795
2013 Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Abstract 3778: Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. Cancer Research. 73: 3778-3778. DOI: 10.1158/1538-7445.Am2013-3778  0.813
2013 Schrecengost R, Dean J, Stanek T, Birbe R, Hicks J, Visakorpi T, DeMarzo A, McMahon S, Knudsen K. Abstract 3576: USP22 modulates AR activity to critically regulate prostate cancer progression. Cancer Research. 73: 3576-3576. DOI: 10.1158/1538-7445.Am2013-3576  0.511
2010 Schuh NR, Guerrero MS, Schrecengost RS, Bouton AH. BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. The Journal of Biological Chemistry. 285: 2309-17. PMID 19940159 DOI: 10.1074/Jbc.M109.046631  0.604
2010 Schrecengost RS, Wilson AL, Guerrero MS, Bouton AH. Abstract 5135: Breast cancer antiestrogen resistance-3 influences breast cancer cell migration by regulating Rac and Rho GTPase signaling Cancer Research. 70: 5135-5135. DOI: 10.1158/1538-7445.Am10-5135  0.808
2008 Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL. The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. Bmc Cancer. 8: 360. PMID 19055839 DOI: 10.1186/1471-2407-8-360  0.318
2008 Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Research. 68: 8796-804. PMID 18974122 DOI: 10.1158/0008-5472.Can-08-2426  0.781
2007 Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Research. 67: 6174-82. PMID 17616674 DOI: 10.1158/0008-5472.Can-06-3455  0.803
2007 Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Letters. 256: 1-24. PMID 17475399 DOI: 10.1016/J.Canlet.2007.03.016  0.707
Show low-probability matches.